Toronto, March 4th, 2022 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has received its Drug Establishment License (DEL) application number (52704) from Health Canada. A site visit is scheduled for the end of May 2022.
“In another step forward for Vivariant, we are proud to have submitted our application for a Drug Establishment License” President & Founder, Thomas Fraleigh said. “In order to test a pharmaceutical drug in Canada, a company must hold a valid DEL. For industries that follow Good Manufacturing Practices (GMP), this is a crucial box to check when selecting a testing partner.”
GMP is an internationally accepted system for ensuring products are consistently produced and controlled according to quality standards. The guidelines are required for pharmaceutical drug manufacture and also implemented by other industries including cannabis, cosmetics, food, and natural health products/dietary supplements.
According to Health Canada, GMP “finished product testing complements the controls used during the manufacturing process. Each fabricator, packager/labeller, distributor and importer must have proper specifications and test methods to help ensure that each drug sold is safe and meets the relevant standard.”
“This opens the door to several new markets for us.” Fraleigh said. “Customers who have a GMP-accredited quality management system themselves expect their quality control lab partner to also be accredited.”
Established in 2017, Vivariant is headquartered in Mississauga, Ontario and specializes in analytical chemistry and microbiology testing services for the Cannabis, Cosmetics, and Dietary Supplement/Natural Health Product industries. Vivariant already holds ISO 17025:2017 accreditation and an Analytical Testing license under the Cannabis Act.
DEL 3-002774-A Under Review – Application 52704